Relationship between ocular surface temperature and 0.1% cyclosporine a in dry eye syndrome with meibomian gland dysfunction

PLoS One. 2023 Nov 20;18(11):e0293472. doi: 10.1371/journal.pone.0293472. eCollection 2023.

Abstract

To determine the relationship between ocular surface temperature (OST) and 0.1% cyclosporine A in patients with dry eye syndrome and meibomian gland dysfunction (MGD). This study retrospectively analyzed 35 eyes from 18 patients with dry eye disease (DED) and MGD, who were divided into two groups. Group 1 was treated with artificial tears, and eyelid margin scrubs without anti-inflammatory eye drops, while group 2 received the same treatment as group 1 along with 0.1% cyclosporine A. The ocular surface disease index (OSDI), tear meniscus height (TMH), noninvasive tear breakup time (NIBUT), lipid layer thickness (LLT), meibum quality score (MQS), and OST were measured at baseline and 1 month later. Nineteen and 16 eyes were included in groups 1 and 2, respectively. Both groups showed a significant decrease in OSDI and OST; however, the decrease was more significant in group 2. No other significant differences in TMH, NIBUT, and LLT were observed; however, MQS significantly differed in group 2. This study found that 0.1% CsA administration can relieve symptoms in patients with DED and MGD although there were no definite keratitis clues, such as epithelial erosion. In addition, the conjunctival temperature showed a correlation with symptom improvement.

MeSH terms

  • Cyclosporine / therapeutic use
  • Dry Eye Syndromes* / diagnosis
  • Humans
  • Meibomian Gland Dysfunction* / drug therapy
  • Meibomian Glands
  • Retrospective Studies
  • Tears
  • Temperature

Substances

  • Cyclosporine

Grants and funding

The authors report the following sources of funding: A grant from Daegu Catholic University in 2022, (20223005) awarded to SHY.